Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Disease Due to Gram-positive Bacteria”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Large-scale testing (Phase 3)Study completedNCT00035269
What this trial is testing

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Who this might be right for
Pneumonia, PneumococcalCommunity Acquired InfectionsGram-positive Bacterial Infections
Pfizer 230
Early research (Phase 1)UnknownNCT02391077
What this trial is testing

A Trial Assessing Efficacy of Various Antimicrobial Techniques for Reducing Bacterial Load

Who this might be right for
Disease Due to Gram-positive Bacteria
Ministry of Health, Rwanda 33
Post-approval studies (Phase 4)Ended earlyNCT00102947
What this trial is testing

Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

Who this might be right for
Soft Tissue Infections
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 72
Not applicableStudy completedNCT03349268
What this trial is testing

Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection

Who this might be right for
Healthcare Associated InfectionClostridium Difficile InfectionInfection Due to Multidrug Resistant Bacteria
University of Michigan 25,732
Large-scale testing (Phase 3)Study completedNCT02142075
What this trial is testing

Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure

Who this might be right for
Renal FailureCritical CareGram Positive Bacteria
Poitiers University Hospital